Molecular characterization of CYP2B6 substrates

被引:39
|
作者
Ekins, Sean [1 ,2 ,3 ]
Iyer, Manisha [4 ]
Krasowski, Matthew D. [4 ]
Kharasch, Evan D. [5 ]
机构
[1] Collaborat Chem, Jenkintown, PA 19046 USA
[2] Univ Maryland, Dept Pharmaceut Sci, Baltimore, MD 21201 USA
[3] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA
[4] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA
[5] Washington Univ, Dept Anesthesiol, Div Clin & Translat Res, St Louis, MO 63110 USA
关键词
ChemSpider; CYP2B6; descriptors; properties; QSAR;
D O I
10.2174/138920008784746346
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
CYP2B6 has not been as fully characterized at the molecular level as other members of the human cytochrome P450 family. As more widely used in vitro probes for characterizing the involvement of this enzyme in the metabolism of xenobiotics have become available, the number of molecules identified as CYP2B6 substrates has increased. In this study we have analyzed the available kinetic data generated by multiple laboratories with human recombinant expressed CYP2B6 and along with calculated molecular properties derived from the ChemSpider database, we have determined the molecular features that appear to be important for CYP2B6 substrates. In addition we have applied 2D and 3D QSAR methods to generate predictive pharmacophore and 2D models. For 28 molecules with Km data, the molecular weight (mean +/- SD) is 253.78 +/- 74.03, ACD/logP is 2.68 +/- 1.51, LogD(pH5.5) is 1.51 +/- 1.43, LogD(pH7.4) is 2.02 +/- 1.25, hydrogen bond donor (HBD) count is 0.57 +/- 0.57, hydrogen bond acceptor (HBA) count is 2.57 +/- 1.37, rotatable bonds is 3.50 +/- 2.71 and total polar surface area (TPSA) is 27.63 +/- 19.42. A second set of 15 molecules without Km data possessed similar mean molecular property values. These properties are comparable to those of a set of 21 molecules used in a previous pharmacophore modeling study (Ekins et al., J Pharmacol Exp Ther 288 (1), 21-29, 1999). Only the LogD and HBD values were statistically significantly different between these different datasets. We have shown that CYP2B6 substrates are generally small hydrophobic molecules that are frequently central nervous system active, which may be important for drug discovery research.
引用
收藏
页码:363 / 373
页数:11
相关论文
共 50 条
  • [21] Regioselectivity of CYP2B6: homology modeling, molecular dynamics simulation, docking
    Bathelt, C
    Schmid, RD
    Pleiss, J
    JOURNAL OF MOLECULAR MODELING, 2002, 8 (11) : 327 - 335
  • [22] Functional characterization of 26 CYP2B6 allelic variants (CYP2B6.2-CYP2B6.28, except CYP2B6.22)
    Watanabe, Takashi
    Sakuyama, Kanako
    Sasaki, Takamitsu
    Ishii, Yuya
    Ishikawa, Masaaki
    Hirasawa, Noriyasu
    Hiratsuka, Masahiro
    PHARMACOGENETICS AND GENOMICS, 2010, 20 (07): : 459 - 462
  • [23] Functional Characterization of CYP2B6 Allelic Variants in Demethylation of Antimalarial Artemether
    Honda, Masashi
    Muroi, Yuka
    Tamaki, Yuichiro
    Saigusa, Daisuke
    Suzuki, Naoto
    Tomioka, Yoshihisa
    Matsubara, Yoichi
    Oda, Akifumi
    Hirasawa, Noriyasu
    Hiratsuka, Masahiro
    DRUG METABOLISM AND DISPOSITION, 2011, 39 (10) : 1860 - 1865
  • [24] Identification and Characterization of CYP2B6 cDNA in Cynomolgus Macaques (Macaca fascicularis)
    Uno, Yasuhiro
    Matsuno, Kiyomi
    Nakamura, Chika
    Utoh, Masahiro
    Yamazaki, Hiroshi
    JOURNAL OF VETERINARY MEDICAL SCIENCE, 2009, 71 (12): : 1653 - 1656
  • [25] Variants in the CYP2B6 3UTR Alter In Vitro and In Vivo CYP2B6 Activity: Potential Role of MicroRNAs
    Burgess, Kimberly S.
    Ipe, Joseph
    Swart, Marelize
    Metzger, Ingrid F.
    Lu, Jessica
    Gufford, Brandon T.
    Thong, Nancy
    Desta, Zeruesenay
    Gaedigk, Roger
    Pearce, Robin E.
    Gaedigk, Andrea
    Liu, Yunlong
    Skaar, Todd C.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 104 (01) : 130 - 138
  • [26] Quantitative in vitro phenotyping and prediction of drug interaction potential of CYP2B6 substrates as victims
    Palacharla, Raghava Choudary
    Nirogi, Ramakrishna
    Uthukam, Venkatesham
    Manoharan, Arunkumar
    Ponnamaneni, Ranjith Kumar
    Kalaikadhiban, Ilayaraja
    XENOBIOTICA, 2018, 48 (07) : 663 - 675
  • [27] CYP2B6 poor metaboliser alleles involved in efavirenz and nevirapine metabolism: CYP2B6*9 and CYP2B6*18 distribution in HIV-exposed subjects from Dschang, Western Cameroon
    Paganotti, Giacomo Maria
    Russo, Gianluca
    Sobze, Martin Sanou
    Mayaka, George Bouting
    Muthoga, Charles Waithaka
    Tawe, Leabaneng
    Martinelli, Axel
    Romano, Rita
    Vullo, Vincenzo
    INFECTION GENETICS AND EVOLUTION, 2015, 35 : 122 - 126
  • [28] Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels: a CYP2B6 gene resequencing study
    Dobrinas, Maria
    Crettol, Severine
    Oneda, Beatrice
    Lahyani, Rachel
    Rotger, Margalida
    Choong, Eva
    Lubomirov, Rubin
    Csajka, Chantal
    Eap, Chin B.
    PHARMACOGENETICS AND GENOMICS, 2013, 23 (02): : 84 - 93
  • [29] Three-dimensional quantitative structure activity relationship analyses of substrates for CYP2B6
    Ekins, S
    Bravi, G
    Ring, BJ
    Gillespie, TA
    Gillespie, JS
    Vandenbranden, M
    Wrighton, SA
    Wikel, JH
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1999, 288 (01): : 21 - 29
  • [30] HTS assay for CYP2B6 and CYP2E1 metabolism and inhibition using fluorogenic VIVID™ substrates
    Marks, BD
    Braun, HA
    Goossens, TA
    Ozers, MS
    Smith, RW
    Lowery, RG
    Trubetskoy, OV
    DRUG METABOLISM REVIEWS, 2002, 34 : 200 - 200